	US 12,016,915 B2
	Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
SangKon Oh, Baltimore, MD (US); Dapeng Li, Davis, CA (US); Jacques Banchereau, Montclair, NJ (US); Gerard Zurawski, Midlothian, TX (US); and Sandra Zurawski, Midlothian, TX (US)
Assigned to BAYLOR RESEARCH INSTITUTE, Dallas, TX (US)
Filed by BAYLOR RESEARCH INSTITUTE, Dallas, TX (US)
Filed on Nov. 9, 2021, as Appl. No. 17/454,108.
Application 13/551,198 is a division of application No. 12/025,010, filed on Feb. 2, 2008, granted, now 8,236,934, issued on Aug. 7, 2012.
Application 17/454,108 is a continuation of application No. 16/372,832, filed on Apr. 2, 2019, granted, now 11,173,202.
Application 16/372,832 is a continuation of application No. 15/265,236, filed on Sep. 14, 2016, granted, now 10,279,030, issued on May 7, 2019.
Application 15/265,236 is a continuation of application No. 14/254,206, filed on Apr. 16, 2014, granted, now 9,453,074, issued on Sep. 27, 2016.
Application 14/254,206 is a continuation of application No. 13/551,198, filed on Jul. 17, 2012, granted, now 8,728,481, issued on May 20, 2014.
Claims priority of provisional application 60/888,036, filed on Feb. 2, 2007.
Prior Publication US 2022/0152192 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/145 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); C07K 14/005 (2006.01); C07K 14/195 (2006.01); C07K 14/37 (2006.01); C07K 14/405 (2006.01); C07K 14/435 (2006.01); C07K 16/28 (2006.01); C12N 5/0784 (2010.01); C12N 7/00 (2006.01)

CPC A61K 39/145 (2013.01) [A61K 47/6849 (2017.08); A61K 51/1027 (2013.01); C07K 14/005 (2013.01); C07K 14/195 (2013.01); C07K 14/37 (2013.01); C07K 14/405 (2013.01); C07K 14/435 (2013.01); C07K 16/28 (2013.01); C12N 5/0639 (2013.01); C12N 7/00 (2013.01); A61K 2039/5154 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01)]

7 Claims

1. A method of delivering an antigen to an antigen presenting cell, comprising administering to the antigen presenting cell an effective amount of a composition comprising a recombinant fusion protein, said fusion protein comprising an anti-human dendritic cell asialoglycoprotein receptor (ASGPR) antibody or an antigen binding fragment thereof and one or more autoimmune antigens, wherein the antibody or fragment thereof comprises (a) an immunoglobulin heavy chain selected from the group consisting of SEQ ID NO: 5, 7, 9, and 11; and (b) an immunoglobulin light chain selected from the group consisting of SEQ ID NO: 6, 8, 10, and 12.